

RETRACTION NOTE

Retraction Note to: Anticancer effects of juglone in OVCAR-3 human ovarian carcinoma are facilitated through programmed cell death, endogenous ROS production, inhibition of cell migration and invasion and cell cycle arrest

Jun-Yu Shi, Zhe-Ren Huang, Hong-Yan Gao, Xiao-Li Xu

Department of Gynecology, the third Affiliated Hospital of Suzhou University (Changzhou First People's Hospital), Changzhou, Jiangsu Province, China, 213003

Retraction note to:

JBUON 2020;25(2):779-784; PMID: 32521867

Following the publication of this article [1], readers drew to our attention that part of the data was unreliable: Figures of this article appeared in other articles (by totally different authors). The authors were requested to provide the raw data and were also asked for an explanation to account for these concerns, however, the Editorial Office hasn't received any reasonable reply. To make the readers alert, we published an Expression of Concern for this article months ago. Now we completed the investigation and decided to retract this article. Authors were informed of the retraction. We thank the readers for bringing this matter to our attention. We apologize for any inconvenience it may cause.

References

1. Shi JY, Huang ZR, Gao HY, Xu XL. Anticancer effects of juglone in OVCAR-3 human ovarian carcinoma are facilitated through programmed cell death, endogenous ROS production, inhibition of cell migration and invasion and cell cycle arrest. JBUON 2020;25(2):779-784.

The original article can be found online at: <https://www.jbuon.com/archive/25-2-779.pdf>

Correspondence to: : Xiao-Li Xu, MD. Department of Gynecology, the third affiliated Hospital of Suzhou University (Changzhou First People's Hospital), No. 185, Juqian Street, Changzhou, Jiangsu Province, China, 213003.
Tel/Fax: +86 519 8618 0000, Email: luciusjohn9999@yahoo.com